AKT1 gRNA (BRDN0001146935) Citations (2)

Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437. PubMed Journal

---

Articles Citing AKT1 gRNA (BRDN0001146935)

Articles
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity. Kostaras E, Kaserer T, Lazaro G, Heuss SF, Hussain A, Casado P, Hayes A, Yandim C, Palaskas N, Yu Y, Schwartz B, Raynaud F, Chung YL, Cutillas PR, Vivanco I. Br J Cancer. 2020 Aug;123(4):542-555. doi: 10.1038/s41416-020-0889-4. Epub 2020 May 22. PubMed
Cellular model system to dissect the isoform-selectivity of Akt inhibitors. Quambusch L, Depta L, Landel I, Lubeck M, Kirschner T, Nabert J, Uhlenbrock N, Weisner J, Kostka M, Levy LM, Schultz-Fademrecht C, Glanemann F, Althoff K, Muller MP, Siveke JT, Rauh D. Nat Commun. 2021 Sep 6;12(1):5297. doi: 10.1038/s41467-021-25512-8. PubMed

If you have published an article using this material, please email us at to have your article added to this page.